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PHARMACEUTICAL FORMULATION FOR
POORLY WATER SOLUBLE
CAMPTOTHECIN ANALOGUES

Silatecan
7-t-butyldimethylsilyl-10
hydroxycamptothecin (DB-67) is an experimental drug
under consideration for clinical testing by the National
Cancer Institute for cancer chemotherapy. As shoWn in FIG.
1, DB-67 is one of a class of A and B ring modi?ed

This application claims the bene?t of US. Provisional

camptothecin analogs. Because of its increased lipophilicity
and dual 7-alkylsilyl and 10-hydroxy substitution, DB-67
displays superior binding to cellular and liposomal mem

Patent Application Serial No. 60/311,570 ?led Aug. 10,
2001.
This invention Was made With Government support
under NCI Contract N01-CM-77108. The Government may

have certain rights in this invention.

10

TECHNICAL FIELD

branes and enhanced drug stability in the presence of human
serum albumin When compared With clinically relevant,
more hydrophilic camptothecin analogues. In vitro cytotox
icity assays indicate that DB-67 is of comparable potency to

other FDA approved camptothecin analogs (e.g., Camptosar

The present invention relates to the ?eld of compositions

and Hycamtin). A viable formulation for intravenous deliv
for treatment of a cancer in an animal. In particular, the
present invention relates to a method for formulating an 15 ery of DB-67 should maintain a desired dose (1—3 mg/mL)

exclusively in the lactone form and of optimal physical and

aqueous solution of a poorly Water-soluble lipophilic camp
tothecin or camptothecin analog, and to compositions for

chemical stability.

mulated thereby.
BACKGROUND OF THE INVENTION

SUMMARY OF THE INVENTION
20

Successful formulation of many neW drug candidates in a

In accordance With the purposes of the present invention

parenteral or oral dosage form is often limited by loW

as described herein, a novel method for formulating an

solubilities of these drugs in an aqueous solution and/or
physical-and chemical instability over a relevant time
period. In recent years, progress has been made in develop

aqueous solution of a lipophilic camptothecin or camptoth
ecin analog, and compositions formulated thereby, are pro
25

ing various solubiliZation formulation approaches, including
salt formation, cosolvent, complexation, mixed micelles/
liposomes, emulsions, and micro/nanoparticles. HoWever,

lipophilic camptothecin or a camptothecin analog, compris

for some very poorly Water-soluble drugs, solubiliZation
approaches are not suf?cient to achieve a desired dosage and

vided. In one aspect, the present invention provides a
method for preparing a stable supersaturated solution of a

30

a supersaturated solution of drugs stable during parenteral or
oral administration may be one of feW alternatives.

ing formulating an alkaline solution of the lipophilic camp
tothecin or camptothecin analog, and acidifying the alkaline
solution in the presence of a solubiliZing agent. The alkaline
solution may be formulated to have a pH of greater than
about 10.0.

The alkaline camptothecin or camptothecin analog may

The inhibition of tumor cell groWth by camptothecin

be acidi?ed by diluting into an acidic solution in the pres

analogues is believed to be linked to their action on DNA

cessful inhibition of DNA topoisomerase I by camptothecin
analogues requires an intact lactone ring (E-ring, species I in

ence of a solubiliZing agent to achieve a ?nal pH of up to
about 6.0. Desirably, the acidic solution may include a buffer
suitable for maintaining a pH of said acidic solution at up to

FIG. 1.) functionality. Camptothecin analogues having open
lactone ring structures (carboxylate form), While quite

about 6.0, for example buffers selected from the group of
buffers consisting of, but not limited to, citrate, acetate,

topoisomerases. Structure-activity studies shoW that suc

soluble in Water, are poorly accumulated by cancer cells,

35

40

exhibit limited activity against the topoisomerase enZyme,
and may be more toxic to healthy cells than the lactone form.

Unfortunately, the E-ring intact lipophilic camptothecin
analogues have a very poor solubility in Water. In the past,
poor solubility has prevented the extensive use of highly
lipophilic camptothecin analogues in clinical treatment of
cancer even though lipophilic camptothecin analogues pro
vide several important advantages over their Water-soluble
counterparts, such as relatively superior tissue penetration/

retention, bioavailability, more consistently optimiZed dos

45

lactate, or any mixture thereof.
The solubiliZing agent may be selected from a group

consisting of a cyclodextrin, a liposome, thermodynamically
stable colloidal dispersions (e.g. micelles or
microemulsions) containing surface-active agents, an
emulsion, or any mixture thereof. Typically, the cyclodextrin
solubiliZing agent may be a Water-soluble [3-cyclodextrin
derivative, selected from the group consisting of sulfobutyl

ether [3-cycllodextrin, 2-hydroxypropyl [3-cyclodextrin, any
other suitably chemically modi?ed [3-cyclodextrin, and any
50

mixture thereof. When liposomes are selected as the solu

biliZing agent, typically they Will be formulated as an acidic
liposomal suspension having a pH of up to about 6.0.

age and schedule for administration, and less interpatient
variability. Indeed, While a number of Water soluble camp

tothecin derivatives including. Camptosar, topotecan,

Suitable thermodynamically stable colloidal dispersions

9-amino-camptothecin, 7-(4-methylpiperaZinomethylene)

may be formulated to have a pH of up to about 6.0, and may
comprise a mixture of a surfactant lipid such as Cremophor

10,11-methylenedioxy camptothecin, 10,11

55

EL, Vitamin E TPGS, various Pluronics (e.g., polyethylene
oxide/polypropylene oxide polymers, TWeen 80), and the

methylenedioxy-camptothecin and 10,11-ethylenedioxy
camptothecin have either been on the market, studied
preclinically, or used in clinical trials to treat certain types of
human cancer, feW clinical studies in human patients involv

ing poorly Water soluble, highly lipophilic camptothecin

like. The dispersions may also contain a Water miscible

co-solvent selected from the group consisting of ethanol,
60

polyethylene glycol (PEG), propylene glycol (PG), glycerol,

analogs [e.g., camptothecin, 10-hydroxy-7-ethyl camptoth

or any mixture thereof. Dextrose or other suitable excipients

ecin (SN38), and silatecan 7-t-butyldimethylsilyl-10
hydroxycamptothecin (DB-67)] have been conducted. This
is largely attributed to the difficulty in developing pharma

may be added to adjust tonicity.

ceutical formulations that alloW the direct administration of

Typically, the lipophilic camptothecin or camptothecin
analog may be camptothecin, silatecan 7-t
65

butyldimethylsilyl-10-hydroxycamptothecin, 10-hydroxy-7

the poorly Water-soluble, active camptothecin lactone spe

ethyl camptothecin, 9-nitrocamptothecin, silatecan 7-t

cies to human patients With cancer.

butyldimethylsilyl-camptothecin, 7-methylcamptothecin,

US 6,653,319 B1
3

4

7-ethylcamptothecin, 7-propylcamptothecin,

illustration of the modes currently best suited to carry out the
invention. As it Will be realiZed, the invention is capable of
other different embodiments and its several details are

7-butylcamptothecin, or mixtures thereof.
In another aspect, a method for preparing a stable super
saturated solution of a lipophilic camptothecin or a

capable of modi?cation in various, obvious aspects all
Without departing from the invention. Accordingly, the
draWings and descriptions Will be regarded as illustrative in

camptothecin-analog is provided, comprising the steps of
solubiliZing the camptothecin or camptothecin analog of

nature and not as restrictive.

choice in an alkaline solution, and diluting the alkaline
solution containing the solubiliZed camptothecin or camp

DESCRIPTION OF THE DRAWINGS

tothecin analog into an acidic solution in the presence of a

solubiliZing agent, selected from the solubiliZing agents as
described above. The properties of the alkaline and acidic

10

solutions are as described above. The desired solubiliZing

present invention and, together With the description, serves
to explain the principles of the invention. In the draWing:

agent may be added to the alkaline solution prior to diluting
the-alkaline solution into the acidic solution, or may be
dissolved into the acidic solution.
The alkaline solution may contain an amount of base (for

The accompanying draWing incorporated in and forming
a part of the speci?cation illustrates several aspects of the

15

FIG. 1 shoWs the schematic structures of the lactone ring

intact DB-67 (species I) and its E-ring opened counterpart

(species II).

example, sodium hydroxide) approximately double the con

FIG. 2 shoWs the dependence of solubility S (mg/mL) for

centration of lipophilic camptothecin or camptothecin ana
log. Typically, the acidic solution Will contain an amount of

DB-67 in aqueous solution at 25° C. on solution pH value.

strong acid, such as for example hydrochloric acid, suf?cient
to neutraliZe the alkaline solution containing camptothecin

E-ring closed DB-67 at 25° C. as a function of cyclodextrin

FIG. 3 shoWs the variation of solubility for the neutral

concentrations (SBE-CD and HP-CD) in aqueous solution.

or camptothecin analog. Buffers may be included in the
acidic solution as described above. Advantageously, the
method as described provides a stable, supersaturated com

position of lipophilic camptothecin or camptothecin analog

FIG. 4 shoWs the variations of DB-67 concentrations for
25

the neutral E-ring closed DB-67 (open circles) and overall
DB-67 concentrations (solid circles) in the supernatant after
1:9 dilution from an alkaline aqueous solution into 22%
(W/v) SBE-CD as a function of time after mixing.
FIG. 5 shoWs the DB-67 concentrations in the ?ltered

Which may be lyophiliZed for long-term storage Without
signi?cant loss of drug activity upon reconstitution.
In yet another aspect of the present invention, a compo
sition suitable for parenteral or oral administration for the

solutions of duplicate samples after reconstitution of the
lyophiliZed formulation. The horiZontal line indicates the
averaged overall DB-67 concentration in the un?ltered solu

treatment of a cancer in an animal is provided, comprising
an aqueous solution containing a therapeutically suf?cient

amount of a lipophilic camptothecin or camptothecin analog
formulated as described above and including the lipophilic
camptothecin or camptothecin analog and a solubiliZing

tions.
FIG. 6 shoWs the variations of DB-67 concentrations for
the overall DB-67 concentrations in the supernatant after 1:9

agent. The lipophilic camptothecin or camptothecin analog

dilution from an alkaline aqueous solution into an acidic

may be included in the composition of the present invention

liposomal suspension (NCS 754057; provided by the

in an amount of from about 0.5 to about 3 mg/mL of
solution.

National Cancer Institute and manufactured by Ben Venue
Laboratories, Inc., Bedford, Ohio 44146) as a function of
time after mixing. The horiZontal line is the overall DB-67

The cyclodextrin and/or liposome solubiliZing agents may

concentration in the sample.

be included in the composition in an amount of from about
10% to about 40% (W/v). In the case Where a thermody

FIG. 7 shoWs the variations of DB-67 concentrations for
the overall DB-67 concentrations in the supernatant after 1:9

namically stable colloidal dispersion (e.g. micelles or
microemulsions) is used as the solubiliZing agent, an aque
ous solution comprising about 12.5% v/v of a polyethoxy
lated lipid such as Cremophor EL and 12.5% v/v ethanol

dilution from an alkaline aqueous solution into acidic solu
45

may be included. In the case Where a liposome is used as a

tion containing 12.5% (v/v) Cremophor EL, 12.5% (v/v)
ethanol, and 4% (W/v) dextrose in Water as a function of time
after mixing. The horiZontal line is the overall DB-67

solubiliZing agent, an acidic liposomal suspension may be
used, containing lipids selected from the group consisting of

concentration in the sample.

egg

preferred embodiments of the invention, examples of Which

phospholipids,

Reference Will noW be made in detail to the presently

cholesterol,

dimyristoylphosphatidylcholine,

are illustrated in the accompanying draWing.

dimyristoylphosphatidylglycerol, or any other suitable lipids
DETAILED DESCRIPTION OF THE
INVENTION

or mixtures thereof.

The compositions manufactured by the method of the
present invention are advantageously more simple and cost

55

invention may be accomplished by various means Which are
illustrated in the examples beloW. These examples are

N-methyl-2-pyrrolidinone). Advantageously, the composi
tions may be lyophiliZed for long-term storage Without
signi?cant loss of drug activity upon reconstitution for

intended to be illustrative only, as numerous modi?cations

and variations Will be apparent to those skilled in the art.
Our earlier studies have shoWn that precipitation occurs

parenteral or oral administration.

Other objects and applications of the present invention
Will become apparent to those skilled in this art from the

folloWing description Wherein there is shoWn and described
a preferred embodiment of this invention, simply by Way of

As summariZed above, the present invention relates to

novel methods for formulating lipophilic camptothecins and
camptothecin analogues, and to compositions formulated
thereby. The methods and compositions of the present

effective to manufacture, provide a therapeutically suitable
dose of poorly Water soluble camptothecin or camptothecin
analog, are stable during storage, and may be formulated to
be free of undesirable organic solvents (e.g., DMSO or

65

immediately during attempts to prepare a supersaturated
solution by mechanically mixing a desired concentration
(e.g., >1 mg/mL ?nal concentration) of lactone-intact DB-67
drug in an organic solvent such as DMSO With a conven

US 6,653,319 B1
5

6

tional dilution medium such as 20% (W/v) sulfobutyl ether
[3-cyclodextrin (SBE-CD). This may be attributed to the high
local concentration of the drugs in their poorly Water-soluble
lactone form in the mixed solution. Aproper control of the
mixing pattern (local or uniform) and rate of addition of the
drugs in their lactone form into the dilution medium has
therefore been key to the success of this type of formulation
approach. HoWever, even With a controlled mixing pattern,
formulation of a supersaturated lactone-intact DB-67 drug
solution by simply adding a concentrated solution of the

desirably beloW about 6.0, and may be regulated by any
buffer suitable for pharmaceutical formulation. Such buffers
include, but are not limited to, citrate, acetate, and lactate.
Another embodiment of this invention is the lyophiliZa
tion of the prepared aqueous solution so that the mixing
procedure described above is conducted by manufacturer
rather than by physician before the administration to a
cancer patient.
10

lactone into an aqueous solution, even in the presence of a

suitable solubiliZing agent, results in precipitation losses of

the drug.

ecin analog. Advantageously, the compositions formulated
by the present method may be formulated to be free of

We then conceived that a supersaturated solution of a

lipophilic camptothecin or camptothecin analog might be
accomplished by employing a chemical approach, rather

15

than a conventional mechanical approach. It has surprisingly
been discovered that a uniform release of camptothecin and

camptothecin analogs may be achieved by converting a
lactone-ring opened camptothecin analog, Which has a high
solubility in Water, to its lactone-ring closed counterpart, and

20

that the rate of this chemical reaction can be regulated by

Example 1
30

tation. Typically, the aqueous solutions contain at least 2

mg/mL DB-67 and 20% (W/v) [3-cyclodextrin derivatives
CD) as solubiliZing agents.

35

Previously, liposomes have been utiliZed to prepare aque
ous suspensions of pharmaceutically active camptothecins.

HoWever, the preparation procedure is usually complex
involving many tedious steps during Which drug loss
(10—20%) is often found to occur. Such losses in drug
concentration are especially dif?cult to control When the

40

component(s). UtiliZing the present invention, the liposomal

complete.
Example 2

50

Example 3
A clear solution comprising a DB-67 concentration of 1

mg/mL in its lactone form and stable for at least three days
Was prepared as folloWs. The DB-67 basic solution Was

process. UtiliZing the present method, We are successful in

prepared as in Example 1.
55

An aliquot of the ?ltered DB-67 basic solution Was mixed

With an acidic EPL-Diluent liposomal suspension (NSC
704057) at a ratio of 1: 19 (v/v). Immediately prior to mixing,

stable solutions With other solubiliZing agents such as a

a suf?cient amount of HCl Was added to the liposomal

suspension to neutraliZe the alkaline DB-67 solution. Citric
60

mulation of aqueous pharmaceutical preparations of poorly
Water-soluble camptothecin analogues using a variety of

acid (2 mM) Was also added to the liposomal suspension to
maintain pH of the ?nal solution at 4.4. The prepared
solution Was incubated for tWo hours until the chemical
conversion Was complete.

solubiliZing agents.
The formulation of the present invention may include a

pharmaceutically acceptable buffer to maintain an acidic pH
such that the camptothecin analogues are preserved in the
active lactone form. Typically, the pH range is maintained

The suspension Was placed on a shaker and incubated With
shaking at 25° C. until the DB-67 Was fully dissolved. It Was
then passed through a 0.2 pm ?lter to remove particulates.
An aliquot of this ?ltered DB-67 basic solution Was then
mixed With a 22.2% (W/v) SBE-CD acidic solution at a ratio
of 1:9 (v/v). A suf?cient amount of HCl Was present in the
?nal solution to neutraliZe the alkaline DB-67 solution.

Cyclodextrin/DB-67 solution Was prepared as in Example
1, except that HP-CD Was used instead of SBE-CD.

mercial sources of liposomes can be used to prepare the

mixture of Cremophor EL and ethanol in Water. Accordingly,
it Will be appreciated that the present method alloWs for

mg/mL in its lactone form and stable for at least three days
Was prepared as folloWs. DB-67 Was accurately Weighed (20
mg/mL) and added to a sodium hydroxide solution having a
NaOH concentration tWice that of the drug concentration.

bated for tWo hours until the chemical conversion Was
45

liposomal formulation, loWering the cost of the manufacture

preparing stable liposomal solutions With negligible loss
(<2%) of DB-67 during the preparation process.
UtiliZing the present method, it is also possible to prepare

A clear solution comprising a DB-67 concentration of 2

Citric acid (2 mM) Was included to maintain the pH of the
?nal solution beloW 4.5. The prepared solution Was incu

suspension is supersaturated With respect to the active
suspension can be prepared in the absence of camptothecin
analogues, and then mixed With a basic camptothecin solu
tion in one ?nal step. Advantageously, this preparation
method minimiZes the loss of the active component(s)
during the preparation process and provides a better control
of formulation quality. Furthermore, since the initial lipo
somal suspension is free of camptothecin analogues, com

teachings provided herein, many variations of the methods
are possible that Will fall Within the scope of the present
invention.

ous solutions containing therapeutically useful concentra

such as SBE-CD or 2-hydroxypropyl [3-cyclodextrin (HP

EXAMPLES
Set forth in greater detail beloW are speci?c details related
to selected modes for carrying out the methods and compo
sitions of the present invention. The examples set forth

invention. Those of skill in the art Will realiZe that, given the
25

administration, Which Would otherWise be subject to rapid
precipitation if other mechanical methods had been
employed. Using the method of the present invention, aque

tions of 1—3 mg/mL camptothecin analogues and 10—40%
(W/v) cyclodextrins may be achieved Without drug precipi

organic solvents (e.g., DMSO or N-methyl-2
pyrrolidinone), in contrast to conventional methods requir
ing use of organic solvents to solubiliZe camptothecin.

herein are in no Way intended to limit the scope of the

controlling solution pH.
It has therefore been found possible to prepare clear stable
aqueous solutions suitable for pharmaceutical

It Will be appreciated by those of skill in the art that the
present invention provides a simple, cost-effective, and safe
method for formulating a therapeutically useful aqueous
solution comprising a lipophilic camptothecin or camptoth

65

Example 4
A clear solution comprising a DB-67 concentration of 2
mg/mL in its lactone form and stable for at least three hours

US 6,653,319 B1
7

8

Was prepared as follows. A solution containing DB-67 and
NaOH Was prepared as described in Example 1. An aliquot

Desirably, the present invention alloWs formulation of super
saturated pharmaceutical formulations With the required
dosage for the lactone-ring intact DB-67 Which are stable
With respect to precipitation Within an appropriate time

of the ?ltered solution Was mixed With an acidic aqueous

cosolvent solution containing 12.5% (v/v) Cremophor EL,

period of administration (e.g., <24 hours).

12.5% (v/v) ethanol, and 4% (W/v) dextrose at a DB-67:
acidic aqueous cosolvent ratio of 1:9 (v/v). Immediately
prior to mixing, a suf?cient amount of HCl to neutraliZe the
alkaline DB-67 solution Was added. Citric acid (5 mM) Was
added also to the solution to maintain the pH of the ?nal
solution at 4.2. The prepared solution Was incubated for tWo
hours until the chemical conversion Was complete.

TABLE 1
Solubilities of DB-67 in various solvent systems at 250 C.3
10 Solvent

S (mg/mL)

Water/30 mM acetate buffer at pH 5.23
Water/0.5 M carbonate buffer at pH 10.20

Example 5

40% (W/v) HPCD/Water
40% (W/v) SBE-CD/Water/l mM HCl

The ?nal solution prepared as described in Example 1 Was
lyophiliZed in a glass vial and sealed With a rubber stopper

40% PG, 10% (v/v) EtOH/Water
10% (v/v) PEG-400/Water
50% (v/v) PEG-400/Water
Emulsion (20% soybean oil, 2% glycerin, 73%
Water, 4% TWeen80, 1% eggPC)

and aluminum cap for long-term storage. The lyophiliZed
preparation may be reconstituted With sterile Water for
administration orally or by a parenteral route to a cancer

Liposome (70:25:5 (mole) DMPC:Chol:DMPG)

patient.
20

Example 6
Solubilities of DB-67 or camptothecin in a given solvent
system Were determined by adding an amount of the drugs
Well in excess of its estimated solubility to 1—2 mL of the
desired solvent in a 4-mL glass vial. The capped vial Was

25

cose units, respectively. With recent development of manu

facturing technology, Water-soluble cyclodextrin derivatives
formed, by alkylation or hydroxyalkylation of the primary
35

hydroxyl groups in cyclodextrins have become less
expensive, and are Widely used in solubiliZation and stabi
liZation of various drug agents because of their capability to
form inclusion complexes With drug molecules having siZe
compatible With the dimensions of the cyclodextrin cavity.

40

As a second characteriZation step, the solubiliZation mecha

nisms for selected [3-cyclodextrins (SBE-CD and HP-CD)
are investigated, as described beloW (Example 7).

Example 7
45

To understand the complexation mechanisms behind this
solubiliZation effect, a solubility method Was employed to
determine the formation constant betWeen a camptothecin

50

maintain an appropriate administration time and volume.
Various solubiliZation approaches such as cosolvents, com

analogue and a cyclodextrin derivative. In the solubility
experiment, the solution pH Was controlled beloW 4.6 With
a 30 mM citrate buffer. As shoWn in FIG. 3, the linear

solubility pro?le for DB-67 complexation With SBE-CD

plexation With Water-soluble cyclodextrins (e.g., SBE-CD
and HP-CD), emulsions, and liposomes failed to accomplish
55

As also shoWn in Table 1 and FIG. 2, a solubility of ~18
mg/mL can be accomplished in an aqueous solution of pH
>10.2. HoWever, as noted above the ioniZed (alkaline)

DB-67 exists mostly in the lactone-ring opened

indicates a predominant formation of 1:1 complexation
betWeen the neutral E-ring closed DB-67 and SBE-CD. In
contrast, a quadratic dependence of DB-67 solubility on
cyclodextrin concentration Was observed for complexation
of the E-ring closed DB-67 With HP-CD, suggesting more
1:2 complexes at a higher HP-CD concentration.
In the limit of [CD]>>SO, the relevant formation constants
can be expressed as:

(carboxylated) form. Previous studies on other camptothecin
analogues indicate that the lactone-ring opened species of a

camptothecin analogue is therapeutically inactive, has a
signi?cantly shorter plasma half life, and exhibits greater
toxicity than the lactone-ring intact species. This is sup
ported by pharmacologic evidence from clinical studies in
humans and other mammalian species receiving sodium
camptothecin, 9-amino camptothecin and Topotecan.

center. The most common cyclodextrins are 01-, [3,

y-cyclodextrins, consisting of 6, 7, and 8 ot-1,4-linked glu

iZation of substituents in DB-67 (10-OH and the —COOH
When the lactone-ring is opened at a basic pH). As noted, the
solubility of DB-67 in an aqueous solution of acidic pH

the desired dosage for DB-67 of 1—2 mg/mL.

pH 10.20 (single).

are cyclic oligosaccharides With a hydrophobic cavity in the
30

The solubility results for DB-67 in various solvent sys
tems are summariZed in Table 1. The solubility-pH pro?le
for DB-67 in aqueous solution is presented in FIG. 2, Where
the curve is a non-least-squares ?t using an equilibrium

(5.2), Where DB-67 exists mostly in E-ring intact form, is
0.11 pg/mL, Well beloW the target dosage of 2 mg/mL to

2.00 X 1071

cyclodextrins (e.g., SBE-CD and HP-CD). Cyclodextrins

detector set at 254 nm, an HP 3392A integrator, and a mobile

model for the base-catalyZed lactone-ring opening and ion

(7.4 1 0.3) X 10*3
(7.5 r 0.2) x 100

The results summariZed in Table 1 indicate that DB-67
can be substantially solubiliZed in the presence of[3

phase of 25% and 41% (v/v) acetonitrile in 2% (W/v)
triethylamine acetate for camptothecin and DB-67, respec

tively.

10*1
X 1071
X 1071
10’2
10*1
X 1071

3mean 1 standard deviation from duplicate samples except in 10% (v/v)
diluent-12 in 5% (W/v) dextrose/Water and Water/0.5 M carbonate buffer at

cm><4.6 mm column and a Discovery C18 2 cm><4.6 mm 5

pm guard column (Supelco), a Beckman 110B solvent
delivery module, a Rheodyne M7125 injector With a 20 pm
injection loop (Rainin), a Waters M2487 Dual )1 Absorbance

(4.9 1 0.2) X
(2.09 1 0.04)
(1.73 1 0.04)
(3.3 r 0.5) x
(2.0 1 0.3) X
(2.06 1 0.05)

Dextrose/Water

rotated in a VWR2010 incubator set at 25° C. for a period

of 3—15 days. The sample Was then passed through a 0.45
pm ?lter, except for liposome or emulsion samples, Which
Were passed through a 1.2 pm ?lter. The collected sample
Was Weighed, diluted With methanol, and analyZed by
HPLC. The HPLC system consisted of a Discovery C18 15

50% Cremophor, 50% (v/v) EtOH (Diluent-12)
5% Cremophor, 5% (v/v) in 5% (W/v)

(1.11 1 0.00) X 1075
1.78 X 10*1

Where S0 is the solubility in the absence of cyclodextrins,
1:1 and
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12 are the 1:1 and 1:2 complex formation

constants, and [CD] is concentration of cyclodextrin. A
linear least-squares ?t of the data for SBE-CD as shoWn in

FIG. 3 yields the complex formation constant of Kfm=

US 6,653,319 B1
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intact DB-67 and SBE-CD are favorable. The inability for

the CD cavity in the 1:2 complexes With HP-CD but not in
the 1:1 complexes, the E-rings in only about 46% DB-67 are
protected from the attack by OH' ions. While not Wishing to

SBE-CD to form 1:2 complexes With DB-67 apparently

be bound by any particular theory, this may explain the

8.5:0.2><103M_1(r2=0.999). The linear behavior also sug
gests that only 1:1 complexes between the neutral E-ring
arises from the presence of an average of seven negatively

approximately 44% reduction in the observed rate constant.

charged sulfobutyl ether groups in a SBE-CD molecule
preventing the approach of tWo SBE-CDs to each other to
form 1:2 complexes. A least-squares ?t of the data for
HP-CD as shoWn in FIG. 3 according to Equation 1 yields
the 1:1 and 1:2 complex formation constants of 1‘1=

On the other hand, in the presence of 20% (W/v) SBE-CD,
more than 99.8% of DB-67 are bound to SBE-CD forming

the predominantly 1:1 complexes. Although there perhaps
10

are a small fraction of 1:1 complexes Where the hydrolysis
site on the lactone-ring is included in the CD cavity, the

5.8:0.2><103M_1 and Kf1‘1=3.8:0.2 ><104M_1(r2=1.000). The

presence of the negatively charged sulfobutyl ether groups

ability of HP-CD to form 1:2 complexes With the E-ring

in SBE-CD may repel the surrounding OH- ions and reduce
the rate for OH' catalyZed hydrolysis reaction.

intact DB-67 suggests that there, are at least tWo binding
sites in the E-ring intact DB-67.
One of the key discoveries in the present invention is the

The signi?cantly reduced rate of hydrolysis to the car
15

utility of the hydrolysis reaction betWeen the lactone-closed
and lactone-opened species (I and II in FIG. 1) to sloWly and
uniformly release lactone-closed camptothecins in a dilution
medium in order to prevent the precipitation of the active

camptothecin analogues and maintain the physical stability

suggests an additional bene?t of the cyclodextrin formula

tions revealed in this invention. The stability of camptoth
ecin analogues in their active lactone form in vivo may
accordingly also increase the half-life of the drugs in human
20

of the formulation. Furthermore, cyclodextrins can not only
solubiliZe camptothecin analogues in Water but also poten

Example 9
25

camptothecin analogues in solution.
Example 8

A successful pharmaceutical formulation With a super

saturated drug concentration requires a physical stability
With respect to drug precipitation. In our ?rst attempt, 20—25
mg/mL of DB-67 Was loaded in DMSO because of the

drug’s high solubility in this solvent. The dissolved DB-67

The reaction kinetics for the E-ring opened and closed
DB-67 Were investigated in aqueous solutions at pH 7.4 and
4.0, respectively. The reactions Were thermostated at
25:0.1° C. by a circulation Water bath and initiated by
adding 0.1 mL of reactants (Species I DB-67 in DMSO or
Species II DB-67 in 2 mM NaOH; see FIG. 1) to a 30 mM

blood, potentially improving bioavailability and therapeutic
usefulness.

tially sloW doWn the E-ring opening hydrolysis reaction in
vivo increasing the lifetime of the drugs in human blood.
Thus, it is necessary to investigate the hydrolysis kinetics of

boxylate form in the presence of [3-cyclodextrin derivatives

30

Was then added sloWly to a 20% (W/v) SBE-CD aqueous
solution by a volume ratio of 1:9 to achieve a ?nal drug
concentration of 2 mg/mL. The dilution rate Was maintained
at 0.10 mL/min. It Was found that the precipitation occurred
even during the mixing process and continued after the

phosphate or acetate buffer solution With an initial reactant 35 ?nish of mixing. Since, DB-67 exists in the lactone-ring

concentration of 2—4><10_6 M. After the addition and at

intact form in DMSO, Which has a very loW solubility in

different time intervals, aliquots of the reaction solutions
Were WithdraWn and immediately assayed by HPLC. The

Water, the local drug concentration near the mixing region is
so large that it is dif?cult to prevent the drugs from under
going fast nucleation and precipitation. Aproper control of
the release pattern (local or uniform) and rate of DB-67 into

concentrations of both species I and II Were monitored in
order to evaluate the mass balance and other possible

40

degradation products. Simultaneous non-linear least-squares

the dilution medium is therefore critical to the success of this

?ts of the kinetic pro?les yield the ?rst-order rate constants

type of formulation approach.

for the lactone-ring opening and closing processes of k
1.1:0.1><10_4 s-1 and kCl0Se=3.3:0.3><10_4 s_1. The mass

into a dilution medium may be accomplished by employing

As described above, a sloW and uniform release of DB-67

balance results indicate that no other reaction processes 45

contribute signi?cantly to the variation of concentrations for
species I and II DB-67.
We have also investigated the hydrolysis processes for the

lactone-ring intact DB-67 (Species I) at pH 7.4 in the
presence of 20% (W/v) SBE-CD and HP-CD, respectively.
The temporal pro?les for the disappearance of species I and

in a controlled fashion. Studies on other camptothecin
analogs suggest that the rate of this chemical reaction can be
50

passed through a 0.2 pm ?lter before it Was added sloWly
55

CD and HP-CD, respectively. As noted above, the presence
of 20% (W/v) SBE-CD or HP-CD reduces the rate for the

lactone-ring opening process by 1.6- and 1.8-fold, respec
tively. The rate reduction is therefore more marked in the
presence of HP-CD.

60

The mechanisms responsible for the improved stability of
the therapeutically viable DB-67 may therefore be different
for use of the solubiliZing agents SBE-CD and HP-CD. In
the case of 20% (W/v) HP-CD, more than 99.9% of DB-67
are included in the CD hydrophobic cavity, among Which
roughly 46% of the complexes are in the form of 1:2

complexes. If the hydrolysis site on the E-ring is included in

regulated by solution pH. Accordingly, 20 mg/mL of DB-67
Was loaded in a sodium hydroxide solution With NaOH
concentration maintained at tWice that of the drug concen
tration. The prepared DB-67 alkaline aqueous solution Was

the appearance of species II Were found to folloW the
?rst-order kinetic models similar to those in the absence of
cyclodextrins. The ?tted rate constants are k0pm=(7.1:0.1)><

1045-1 and k0pm=(6.2:0.1)><10_5s_1 for 20% (W/v) SBE

a chemical approach, namely by converting the E-ring
opened DB-67 (Species II, see FIG. 1), Which is highly
Water-soluble, to the neutral E-ring closed DB-67 (Species I)

(0.11 mL/min) into 20% (W/v) acidic SBE-CD solution by a
volume ratio of 1:9. In order to completely neutraliZe
DB-67, HCl Was present in the dilution solution in an
amount equal to the amount of NaOH in the DB-67 alkaline
solution. A small amount of acetate buffer (5 mM) Was also
included in the dilution medium to control the solution pH
to about 4 in order to facilitate a timely conversion from the

E-ring opened DB-67 to its E-ring closed counterpart.
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FIG. 4 shoWs the overall DB-67 concentration and the
concentration of converted lactone-intact DB-67 in the solu
tion at different time intervals. Overall DB-67 concentration
remained constant over an extended period of three days,

exceeding the target stability time of less than one day. At

US 6,653,319 B1
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the measured solution pH of 4.4, the E-ring closed DB-67

5. The method of claim 4, Wherein said buffer is selected
from the group of buffers consisting of citrate, acetate,
lactate, and any mixture thereof.

slowly built up in the ?nal solution in a uniform manner and

the process Was nearly complete Within 100 minutes. This
sloW and uniform build-up of the lactone-ring intact DB-67

6. The method of claim 1, Wherein said solubiliZing agent

may explain the superior stability of this formulation
approach in comparison With the simple mechanical method

is selected from the group consisting of a cyclodextrin, a

using DMSO as a solubiliZing agent.

an emulsion, and any mixture thereof.
7. The method of claim 6, Wherein said cyclodextrin is a

Example 10
For long-term storage, the ?nal solution containing 20%
(W/v) SBE-CD and about 2 mg/mL lactone-ring intact
DB-67 prepared according to the procedure described above

liposome, a thermodynamically stable colloidal dispersion,

Water-soluble [3-cyclodextrin derivative.
10

sisting of sulfobutyl ether [3-cyclodextrin, 2-hydroxypropyl

Was lyophiliZed after the chemical conversion process Was

nearly completed (>90%). Shortly after the lyophiliZation,
the lyophiliZed sample Was reconstituted and the stability of
the reconstituted solution Was examined folloWing the same
procedure as described above. The results are presented in

15

10. The method of claim 6, Wherein said thermodynami
cally stable colloidal dispersion is formulated to have a pH

days, suggesting that no signi?cant occurrence of

of up to about 6.0.

nucleation/precipitation during the lyophiliZation process
20

Example 11
The precipitation pro?les of DB-67 solutions containing
other solubiliZing agents such as liposomes and an acidic
aqueous cosolvent solution comprising an equal volume
mixture of ethanol and cremophor, prepared as described in
Examples 3 and 4, respectively, Were evaluated. The stabil

11. The method of claim 10, Wherein said thermodynami
cally stable colloidal dispersion comprises a surfactant lipid.
12. The method of claim 11, Wherein said surfactant lipid
is selected from the group consisting of Cremophor, Vitamin

E TGPS, polyethylene oxide/polypropylene oxide polymers,
25

ity pro?les are presented in FIGS. 6 and 7. The liposome/
DB-67 solutions Were stable for more than three days (FIG.
6). The acidic aqueous cosolvent/DB-67 solutions Were

[3-cyclodextrin, and any mixture thereof.
9. The method of claim 6, Wherein said liposome is
formulated as an acidic liposomal suspension having a pH of
up to about 6.0.

FIG. 5. The reconstituted solution Was stable for about seven

and Within about seven days after reconstitution.

8. The method of claim 7, Wherein said Water-soluble
[3-cyclodextrin derivative is selected from the group con

TWeen 80, and any mixture thereof.
13. The method of claim 11, Wherein said thermodynami
cally stable colloidal dispersion includes a Water miscible
co-solvent selected from the group consisting of ethanol,

polyethylene glycol, polypropylene glycol, glycerol, and
30

any mixture thereof.

14. The method of claim 11, Wherein said thermodynami
cally stable colloidal dispersion includes an agent for adjust

stable for more than three hours. Dynamic light scattering
measurements indicated that the average particle siZe in the

acidic liposomal suspensions (pH 2.1 and 4.6) remained in

ing tonicity selected from the group consisting of dextrose,

a narroW range of 74—79 nm during ?ve days’ incubation,

sodium chloride, and any mixture thereof.
15. The method of claim 1, Wherein said lipophilic
camptothecin or camptothecin analog is selected from the

suggesting that the acidic liposomal suspension is stable for
at least ?ve days (FIG. 6).
The foregoing description of preferred embodiments of

35

group consisting of camptothecin, silatecan 7-t

butyldimethylsilyl-10-hydroxycamptothecin, 10-hydroxy-7

the invention has been presented for purposes of illustration

ethyl camptothecin, 9-nitrocamptothecin, silatecan 7-t

and description. It is not intended to be exhaustive or to limit

the invention to the precise form disclosed. Obvious modi
?cations or variations are possible in light of the above
teachings. The embodiments Were chosen and described to
provide the best illustration of the principles of the invention
and its practical application to thereby enable one of ordi
nary skill in the art to utiliZe the invention in various

40

7-butylcamptothecin, and any mixture thereof.
16. A method for preparing a stable supersaturated aque
ous solution of a lipophilic camptothecin or a camptothecin
45

embodiments and With various modi?cations as are suited to

diluting said alkaline solution containing said solubiliZed
50

equitably entitled.
What is claimed is:
1. Amethod for preparing a stable supersaturated aqueous
solution of a lipophilic camptothecin or a camptothecin

analog, comprising formulating an alkaline solution of said
lipophilic camptothecin or camptothecin analog, and acidi

55

agent.
2. The method of claim 1, Wherein said alkaline solution
60

3. The method of claim 1, Wherein said alkaline camp

tothecin or camptothecin analog is acidi?ed by diluting said
alkaline solution into an acidic solution in the presence of a

solubiliZing agent to achieve a ?nal pH of up to about 6.0.
4. The method of claim 3, Wherein said acidic solution
includes a buffer suitable for maintaining a pH of said acidic
solution at up to about 6.0.

camptothecin or camptothecin analog into an acidic
solution in the presence of a solubiliZing agent.
17. The method of claim 16, Wherein said solubiliZing
agent is added to said alkaline solution of camptothecin or

camptothecin analog prior to diluting the alkaline solution

fying said alkaline solution in the presence of a solubiliZing

is formulated to have a pH of at least 10.0.

analog, comprising the steps of:
solubiliZing said camptothecin or camptothecin analog in
an alkaline solution; and

the particular use contemplated. All such modi?cations and
variations are Within the scope of the invention as deter

mined by the appended claims When interpreted in accor
dance With the breadth to Which they are fairly, legally and

butyldimethylsilyl camptothecin, 7-methylcamptothecin,
7-ethylcamptothecin, 7-propylcamptothecin,
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into the acidic solution.
18. The method of claim 16, Wherein said alkaline solu
tion has a pH of at least about 10.0.
19. The method of claim 16, Wherein said alkaline solu
tion is diluted into said acidic solution to achieve a ?nal pH
of up to about 6.0.
20. The method of claim 16, Wherein said acidic solution
includes a buffer suitable for maintaining a ?nal pH in said
acidic solution of up to about 6.0.
21. The method of claim 20, Wherein said buffer is

selected from the group of buffers consisting of citrate,
acetate, lactate, and any mixture thereof.
22. The method of claim 16, Wherein said solubiliZing
agent is selected from the group consisting of a cyclodextrin,

US 6,653,319 B1
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a liposome, a thermodynamically stable colloidal dispersion,

39. The composition of claim 35, Wherein said thermo
dynamically stable colloidal dispersion is formulated to have

an emulsion, and any mixture thereof.

23. The method of claim 22, Wherein said cyclodextrin is

a pH of up to about 6.0.

a Water-soluble [3-cyclodextrin derivative.
24. The method of claim 23, Wherein said Water-soluble
[3-cyclodextrin derivative is selected from the group con

sisting of sulfobutyl ether [3-cyclodextrin, 2-hydroxypropyl
[3-cyclodextrin, and any mixture thereof.
25. The method of claim 22, Wherein said liposome is
formulated as an acidic liposomal suspension having a pH of

10

up to about 6.0.

26. The method of claim 22, Wherein said thermodynami
cally stable colloidal dispersion is formulated to have a pH

dynamically stable colloidal dispersion includes a Water
miscible co-solvent selected from the group consisting of

of up to about 6.0.

27. The method of claim 26, Wherein said thermodynami
cally stable colloidal dispersion comprises a surfactant lipid.

15

E TGPS, polyethylene oxide/polypropylene oxide polymers,
20

polyethylene glycol, polypropylene glycol, glycerol, and
any mixture thereof.

ethanol, polyethylene glycol, polypropylene glycol,
glycerol, and any mixture thereof.
43. The composition of claim 39, Wherein said thermo
dynamically stable colloidal dispersion includes an agent for

28. The method of claim 27, Wherein said surfactant lipid
is selected from the group consisting of Cremophor, Vitamin
TWeen 80, and any mixture thereof.
29. The method of claim 26, Wherein said thermodynami
cally stable colloidal dispersion includes a Water miscible
co-solvent selected from the group consisting of ethanol,

40. The composition of claim 39, Wherein said thermo
dynamically stable colloidal dispersion comprises a surfac
tant lipid.
41. The composition of claim 40, Wherein said surfactant
lipid is selected from the group consisting of Cremophor,
Vitamin E TGPS, polyethylene oxide/polypropylene oxide
polymers, TWeen 80, and any mixture thereof.
42. The composition of claim 39, Wherein said thermo

adjusting tonicity selected from the group consisting of
dextrose, sodium chloride, and any mixture thereof.
44. The composition of claim 33, Wherein said lipophilic
camptothecin or camptothecin analog is included in an
amount of from about 0.5 to about 3 mg/mL of solution.

25

30. The method of claim 26, Wherein said thermodynami
cally stable colloidal dispersion includes an agent for adjust

45. The composition of claim 35, Wherein said cyclodex
trin solubiliZing agent is included in an amount of from
about 10% to about 40% W/v.

ing tonicity selected from the group consisting of dextrose,

46. The composition of claim 35, Wherein said liposome

sodium chloride, and any mixture thereof.
31. The method of claim 16, Wherein said lipophilic
camptothecin or camptothecin analog is selected from the

solubiliZing agent is included in an amount of from about
10% to about 40% W/v.

30

47. The composition of claim 35, Wherein said thermo

group consisting of camptothecin, silatecan 7-t

dynamically stable colloidal dispersion comprises-an aque

butyldimethylsilyl-10-hydroxycamptothecin, 10-hydroxy-7
ethyl camptothecin, 9-nitrocamptothecin, silatecan 7-t

butyldimethylsilyl camptothecin, 7-methylcamptothecin,
7-ethylcamptothecin, 7-propylcamptothecin,

35

7-butylcamptothecin, and any mixture thereof.
32. The method of claim 16, further including the step of
40

animal, comprising an aqueous solution containing a thera
peutically sufficient amount of a lipophilic camptothecin or

dimyristoylphosphatidylcholine,
45 solution comprises an amount of an acid suitable for neu

traliZing said alkaline camptothecin or camptothecin analog

34. The composition of claim 33, Wherein said lipophilic
camptothecin or camptothecin analog is selected from the
group consisting of camptothecin, silatecan 7-t

butyldimethylsilyl-10-hydroxycamptothecin, 10-hydroxy-7

solution.

50

ethyl camptothecin, 9-nitrocamptothecin, silatecan 7-t

butyldimethylsilyl camptothecin, 7-methylcamptothecin,
7-ethylcamptothecin, 7-propylcamptothecin,
7-butylcamptothecin, and any mixture thereof.
35. The composition of claim 33, Wherein said solubiliZ
ing agent is selected from the group consisting of a
cyclodextrin, a liposome, a thermodynamically stable col
loidal dispersion, an emulsion, and any mixture thereof.
36. The composition of claim 35, Wherein said cyclodex
trin is a Water soluble [3-cyclodextrin derivative.

51. The composition of claim 50, Wherein said acid is
selected from the group consisting of hydrochloric acid,
phosphoric acid, carbonic acid, formic acid, acetic acid,
lactic acid, citric acid, and any mixture thereof.
52. The composition of claim 33, Wherein said alkaline
solution includes an amount of base double the amount of

55

camptothecin or camptothecin analog.
53. The composition of claim 52, Wherein said base is
selected from the group consisting of sodium hydroxide,
potassium hydroxide, sodium carbonate, and any mixture
thereof.

60

37. The composition of claim 36, Wherein said Water
soluble [3-cyclodextrin derivative is selected from the group

54. The composition of claim 33, Wherein said acidic
solution includes a-buffer suitable for maintaining a pH of
the acidic solution at up to about 6.0.

consisting of sulfobutyl ether [3-cyclodextrin,
2-hydroxypropyl [3-cyclodextrin, and any mixture thereof.
38. The composition of claim 35, Wherein said liposome

49. The composition of claim 38, Wherein said acidic
liposomal suspension includes lipids selected from the group
consisting of egg phospholipids, cholesterol,
dimyristoylphosphatidylglycerol, and any mixture thereof.
50. The composition of claim 33, Wherein said acidic

camptothecin analog formulated by the steps of solubiliZing
said camptothecin or camptothecin analog in an alkaline
solution, and diluting said alkaline solution into an acidic
solution in the presence of a solubiliZing agent.

48. The composition of claim 34, Wherein said camptoth
ecin analogue is silatecan 7-t-butyldimethylsilyl-10

hydroxycamptothecin.

lyophiliZing the stable, supersaturated solution for storage.
33. A composition for the treatment of a cancer in an

ous solution of about 12.5% v/v Cremophor EL and 12.5%
v/v ethanol.
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55. The composition of claim 54, Wherein said buffer is
selected from the group of buffers consisting of citrate,
acetate, lactate, and any mixture thereof.

is formulated as an acidic.liposomal suspension having a pH
of up to about 6.0.
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